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Abstract. In our previous studies, sulfatase 2 (Sulf2) was found 
to upregulate vascular endothelial growth factor-D (VEGF-D) 
expression in breast cancer. As VEGF-D plays an important role 
in lymphangiogenesis, we hypothesized that Sulf2 facilitates 
lymphangiogenesis in breast cancer by regulating VEGF-D. 
To evaluate the functions of Sulf2 on lymphangiogenesis in 
breast cancer, proliferation, apoptosis, cell cycle, cell mobility 
and tube-formation of lymphatic endothelial cells (LECs) were 
measured in vitro. Lymphangiogenesis in nude mouse ears and 
breast cancer xenografts were examined in vivo. Furthermore, 
the expression levels of related signaling pathway genes were 
screened and verified in LECs. We found that Sulf2 signifi-
cantly increased the mobility and tube formation of the LECs, 
inhibited cisplatin-induced LEC apoptosis, but had no effect 
on cell proliferation and the cell cycle. Moreover, recombinant 
Sulf2 (rSulf2) combined with VEGF-D further promoted 
the proliferation, cell cycle, mobility and tube-like struc-
ture formation in the LECs, and at the same time inhibited 
cisplatin-induced apoptosis especially in the late stage. Sulf2 
also significantly increased the density of lymphatic vessels 
in mouse ears and breast cancer xenografts in vivo. AKT1 
was also shown to be upregulated and activated by Sulf2. Our 
results confirmed that Sulf2 facilitated lymphangiogenesis 
in breast cancer cells by regulating VEGF-D and that the 
AKT1-related signaling pathway was involved.
Introduction
Extracellular sulfatases, especially heparan endosulfa-
tases (Sulfs), play important roles in cancer progression by 
modifying the sulfate patterns of heparan sulfate proteo-
glycans (HSPGs) located on the surface of most animal 
cells (1-3). HSPGs can be released into the extracellular matrix 
and can also be detected in serum. HSPGs carry out many 
structural and signaling functions through binding to protein 
ligands (4,5). The Sulf family includes two structurally similar 
endogenous sulfatases (Sulf1 and Sulf2) with 64% homology 
in highly conserved heparin-binding domains, but with 
different functions (2-4). Sulfatase 2 (Sulf2) is an extracel-
lular endoglucosamine-6-sulfatase and considered as a bona 
fide cancer-causing agent in multiple types of cancer (6,7). 
Sulf2 is overexpressed in many tumor cells and was shown 
to promote tumorigenesis in many human cancers such as 
hepatocellular (8), pancreatic (9), ovarian (10), breast (6,10), 
and non-small cell lung carcinoma (11). Sulf2 also increased 
the activities of growth factors such as vascular endothelial 
growth factor (VEGF) and fibroblast growth factor-1 (FGF-1), 
and certain chemokines such as stromal cell-derived 
factor-1 (SDF-1) and secondary lymphoid-tissue chemo-
kine (SLC), stimulating the biological functions of endothelial 
cells to promote angiogenesis (5,12). Although Sulf2 was 
confirmed to facilitate angiogenesis, the effect of Sulf2 on 
lymphangiogenesis in tumors is still unknown.
Lymphangiogenesis, which is the formation of new 
lymphatic vessels, is a common process in normal tissue 
development, inflammation, wound healing and lymphatic 
edema (13,14). Recently, more and more research has found 
lymphangiogenesis to play an important role in tumor 
progression and metastasis (15,16). New lymphatic vessels are 
composed of one single layer of lymphatic endothelial cells. The 
basement membranes of new lymphatic vessels are incomplete, 
and the endothelial cells do not connect tightly. These factors 
allow tumor cells to easily invade new lymphatic vessels and 
metastasize to regional lymph nodes or distant organs (15-18). 
In recent years more research oncologists are becoming inter-
ested in the mechanisms of tumor-induced lymphangiogenesis 
in various tumors (19,20). Breast cancer is one of the most 
common types of cancer among women worldwide (21,22). 
Over 50% of early-stage breast cancer patients have local 
lymph node metastasis (18). Moreover, regional lymph node 
metastasis in breast cancer is also one of the main factors that 
leads to breast cancer metastasis and poor prognosis (23,24). 
Tumor size and regional lymph node metastasis are used as 
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biological indicators for breast cancer classification and selec-
tion markers for treatment strategies. Vascular endothelial 
growth factor-C (VEGF-C) and VEGF-D could combine with 
vascular endothelial growth factor receptor-3 (VEGFR-3) 
to induce lymphangiogenesis (20,25,26). Our previous 
studies also suggested that breast cancer patients with high 
VEGF-D expression would have more regional lymph node 
metastasis, poor disease-free survival (DFS) and poor overall 
survival (OS) (20,25). Karpanen et al (24) demonstrated that 
when VEGF-D-overexpressing cells were implanted into 
transgenic mice, tumor-associated lymphangiogenesis was 
induced in several orthotopic mouse models.
Previously, we demonstrated that VEGF-D/FIGF, a 
member of the VEGF family, was upregulated by Sulf2 (6). In 
this study, we hypothesized that Sulf2 facilitates lymphangio-
genesis in breast cancer by regulating VEGF-D. To evaluate 
the functions of Sulf2 in lymphangiogenesis in breast cancer, 
we examined the proliferation, apoptosis, cell cycle, mobility 
and tube-like structure formation of LECs in vitro, as well 
as lymphangiogenesis in mouse ears and xenografts in vivo. 
The expression of related signaling pathway genes was also 
screened and verified in LECs.
Materials and methods
Cell lines. Human breast cancer cell lines (MCF-7, 
MDA-MB-231) were purchased from the The Cell Bank 
of the Chinese Academy of Sciences (Shanghai, China). 
HEK293T cells used for lentivirus packaging were stocked 
in our own laboratory. All cells were cultured in Dulbecco's 
modified Eagle's medium (DMEM; HyClone Laboratories, 
Inc., Logan, UT, USA) with 10% fetal bovine serum (FBS) 
and penicillin-streptomycin (all from Gibco, Grand Island, 
NY, USA). LECs were cultured in Endothelial Cell Growth 
Medium (ECGM) (both from PromoCell, Heidelberg, 
Germany). All cells were cultured at 37˚C in 5% CO2.
Conditioned medium (CM) collection. CM was collected from 
the supernatant of MCF-7 cells. MCF-7 cells release high 
levels of Sulf2 protein in the supernatant which was confirmed 
in our previous study (6). The MCF-7 cells were cultured in 
DMEM until 80% confluence and were subsequently cultured 
in OptiMEM (HyClone Laboratories, Inc.) for another 72 h. 
The supernatant was collected and concentrated using Amicon 
Ultra filters 30 D (Millipore, Billerica, MA, USA) and then 
was kept in 50 mM HEPES buffer (pH 8.0; Biochrom GmbH, 
Berlin, Germany) for further study.
Flag-Sulf2 vector construct. The signal peptide sequence of 
Sulf2 was removed. The new peptide sequences of signal Flag 
and Ig-k were added with three rounds of PCR using three 
forward primers (Table I) and reverse primer 5'-CGG 
GATCCTTAACCTTCCCAGCCTTCCC-3'. The PCR condi-
tions were 95˚C for 5 min, followed by 35 cycles of 
amplification, 95˚C for 15 sec, 55˚C for 15 sec and 72˚C for 
1 min. The PCR sequence structures of flag-Sulf2 were signal 
peptide, signal peptide cleavage site, Flag, the linker portion of 
GSG and the Sulf2 cDNA sequence (Table Ⅱ). The amplified 
fragment was cloned into the pCDH (System Biosciences, 
Mountain View, CA, USA) to form the pCDH-Flag-Sulf2 
vector construct. The sequences of the positive clone were 
identified using enzyme digestion and gene sequencing detec-
tion (Shanghai Meiji, Shanghai, China).
rSulf2 combination and purification. The pCDH-Flag-Sulf2 
lentivirus was packaged in HEK293F cells using 
Lipofectamine 2000 (Invitrogen Life Technologies, Carlsbad, 
CA, USA) according to the manufacturer's instructions. The 
supernatant from the lentivirus-transfected HEK293F cells 
was collected and incubated with anti-Flag/M2 agarose 
beads (Sigma-Aldrich, St. Louis, MO, USA) at 4˚C over-
night. The beads were washed three times with washing 
buffer. The bound proteins were eluted with 0.1 mg/ml 
Flag peptide (DYKDDDDK). The eluate was concentrated 
though Amicon Ultra filters 30 D and kept in 50 mM HEPES 
buffer (pH 8.0).
qRT-PCR analysis. Total RNA was isolated from cells using 
TRIzol reagent and reverse transcribed into cDNA using 
SuperScript III Reverse Transcriptase (both from Invitrogen 
Madison, WI, USA). The mRNA level was determined 
using the 7900HT qRT-PCR system (Applied Biosystems, 
Foster City, CA, USA) using SYBR® Green Real-time PCR 
Master Mix (Takara, Shiga, Japan). Primers for qRT-PCR 
are listed in Table Ⅲ. Glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) was used as an internal control. Relative 
mRNA levels were calculated using the ΔΔCt method.
Western blot (WB) analysis. Cells were harvested in the pres-
ence of a protease inhibitor cocktail (Sigma-Aldrich) in RIPA 
lysis buffer (Beyotime, Jiangsu, China). Equal amounts of 
proteins from the cells were resolved on SDS-PAGE and then 
transferred onto PVDF membranes as previously described (6). 
The membranes were separately probed with rabbit anti-FIGF 
(1:1,000, PAB4879; Abnova, Atlanta, GA, USA), rabbit 
anti-AKT1 (1:1,000, ab32505), rabbit anti-pAKT1 (s473) 
(1:1,000, ab66138; both from Abcam, Cambridge MA, USA), 
rabbit anti-mouse LYVE-1 (1:1,000, ab36993; AngioΒio, San 
Diego, CA, USA), rabbit anti-GAPDH (1:500; Sigma-Aldrich) 
for 1 h. Subsequently, the membranes were washed with 
TBST, and then incubated with goat anti-rabbit HRP (1:500; 
Sigma-Aldrich) for 1 h. Bound antibody chemiluminescence 
was detected using chemiluminescence kits (Thermo Fisher 
Scientific, Darmstadt, Germany). The optical density was 
determined using a scanning densitometer and analyzed using 
Quantity One software (Bio-Rad, Hercules, CA, USA).
Proliferation assay. LECs were divided into four groups 
(control-1, rSulf2, VEGF-D, rSulf2+VEGF-D). Control-1 was 
cultured with only DMEM media. The other groups were sepa-
rately cultured with rSulf2, VEGF-D and rSulf2+VEGF-D. 
The final concentration of rSulf2 and VEGF-D in each group 
was 50 ng/ml. The proliferation of LECs was assessed by 
the MTT method. Cells were dissociated from cell flasks 
by trypsin (Sigma-Aldrich) digestion and were seeded into 
96-well plates (1x105 cells/ml). The proliferation of LECs in 
the four groups was detected at different time-points (0, 12, 
24, 36 and 48 h). All cells were incubated at 37˚C for 4 h 
followed by the addition of 10 µl MTT (5 mg/ml) and 100 µl 
DMSO. The absorbance value of each well was measured 
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using a microplate reader (Bio-Tek, Winooski, VT, USA) at a 
wavelength of 570 nm.
Apoptosis assay. The aforementioned four groups were 
used. Apoptosis was determined by dual staining using 
Annexin V/FITC and propidium iodide (Invitrogen). Briefly, 
the log phase of LECs was seeded into 24-well cell culture 
plates (1x105 cells/well). Subsequently, LECs were treated 
with 10 µg/ml cisplatin (Qilu Pharmaceutical Co., Shanghai, 
China) for 24 h and then dissociated from the wells with 
0.25% trypsin, spun at 1,500 rpm for 5 min, resuspended 
in Annexin V binding buffer, stained with 1 µl Annexin V/
FITC for 15 min and 1 µl propidium iodide for 1 min. The 
cells were analyzed using the FACSCalibur System (BD 
Biosciences, San Jose, CA, USA). The relative proportion of 
Annexin V-positive cells, representing apoptotic cells, was 




Flag-Sulf2 F3(Nhe I) 5'-CTAGCTAGCATGGAGACAGACACACTCCTGCTATGGGTACTGCTGCTCTGG-3'
Table II. DNA sequences and amino acid sequences of flag-Sulf2.
Genes DNA sequence Amino acid sequence
Signal peptide ATGGAGACAGACACACTCCTGCTATGGGTA METDTLLLWVL
 CTGCTGCTCTGGGTTCCAGGTTCCACTGGT LLWVPGST




 (Sulf2 full length...) (Sulf2 full length
  amino acid chain...)
Table Ⅲ. Real-time PCR primers.
Gene Primer sequences Length (bp)
GAPDH (HUMAN) F 5'-GGGAAACTGTGGCGTGAT-3' 299
 R 5'-GAGTGGGTGTCGCTGTTGA-3'
PLA2G1B F 5'-TGTGGCAGTTCCGCAAAAT-3' 77
 R 5'-GCAGCCGTAGTTGTTGTATTCC-3'
PLA2G5 F 5'-AACCCCAGAGATGAAAGGC-3' 134
 R 5'-CGTAGTTTGTCAGGGCGTTC-3'
PLA2G6 F 5'-CCACATCATCCCTTCTCCCT-3' 181
 R 5'-CTTTCACTCCTCCTCCATCCA-3'
PLA2G2D F 5'-GGCCTAGAGTGGCAAATGG-3' 104
 R 5'-GGGAAAACAGGGGAAACAGA-3'
AKT1 F 5'-GCCCTGCTACCTGTTCTTGG-3' 266
 R 5'-AAGCAAATGGCAAAGTGTGAG-3'
PIK3R1 F 5'-TTGGAAGCAGCAACCGAAAC-3' 123
 R 5'-CTTCGCCGTCCACCACTACA-3'
PIK3R3 F 5'-TGGTTCAGCACAACGACTCC-3' 99
 R 5'-CACCTCTCTTCCCACTTCCT-3'
F, forward; R, reverse.
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determined using FlowJo software (FlowJo, LLC, Ashland, 
OR, USA).
Cell cycle assay. The aforementioned four groups were used. 
The cell cycle distribution of LECs was determined by prop-
idium iodide staining and flow cytometric analysis. After LECs 
were treated with 10 µg/ml cisplatin for 24 h, the cells were 
dissociated from the wells with 0.25% trypsin. Subsequently, 
they were fixed in 70% ethanol overnight at -20˚C and incu-
bated in RNase A at 37˚C for 30 min. Propidium iodide was 
then added and the cells were incubated in a dark room for 
30 min. Flow cytometry was used to detect the cell cycle 
distribution. The proliferation index (PI) was calculated using 
the formula PI = (S + G2)/(S + G1 + G2) x 100%.
LEC mobility assay. The aforementioned four groups were 
used. The mobility of LECs was determined in 12-well 
Boyden chamber plates and polycarbonate membrane filter 
inserts (CoStar Group, Inc., Washington, DC, USA) with 
8-µm pores. For the cell mobility assay, the interior of the 
Transwell insert was coated with Matrigel (BD Pharmingen, 
San Diego, CA, USA), which mimics the basement membrane. 
In all, 1x105 cells were seeded into the upper chamber. The cell 
suspension was also seeded onto the membrane in the upper 
chamber and the lower chamber was filled with 1 ml medium 
with 10% FBS. After 48 h, the non-migrating cells on the 
surface of the upper chamber were removed with cotton swabs. 
The migrating cells at the bottom of the membrane were fixed 
in formaldehyde for 1 min and then stained with crystal violet. 
The stained membranes were cut and placed onto a glass slide 
and the number of invading cells at the bottom surface of the 
membrane was counted three times under a bright-field light 
microscope.
Lymphatic tube-like structure formation assay. The aforemen-
tioned four groups were used. The lymphangiogenic capacities 
of LECs on Matrigel were determined according to the manu-
facturer's instructions. The Matrigel was melted in 4˚C and 
was diluted to half its concentration by media and then was 
added into 24-well plates for cooling down. The 24-well plates 
were placed in an incubator for 30 min to solidify the glue. 
LECs (5x105) were digested and added into each well before 
this solidification process. The numbers of new lymphatic 
tubes were detected using an inverted phase contrast micro-
scope (AMG, Bovenden, Germany) after 24 h of culture.
Lymphangiogenesis in mouse ears. Four-week-old, BALB/
c-nu mice (weight, 15 g) were purchased from the Shanghai 
Experimental Animal Center of the Chinese Academy of 
Sciences (Shanghai, China). The mice were divided into 
three groups (control-2, CM-nu, rSulf2-nu). A total of 0.1 ml 
0.9% saline, CM (50 mM) and rSulf2 (50 mM) were sepa-
rately injected into the root of the mouse ears every day for 
six weeks. Excised mouse ears were fixed in formalin buffer 
and embedded in paraffin for advanced testing. All experi-
mental protocols followed the instructions of the Chinese 
Council on Animal Care and were approved by the Animal 
Experimental Ethical Inspection of Shanghai Ninth People's 
Hospital affiliated to Shanghai Jiaotong University, School of 
Medicine [permit (no. 20015) 25].
Lymphangiogenesis in breast cancer xenografts. Six-week-old, 
18-g female Nod/scid mice were purchased from Shanghai 
Experimental Animal Center of the Chinese Academy of 
Sciences. MDA-MB-231 breast cancer cells were detached with 
0.25% trypsin and resuspended in HBSS/Matrigel (1:1 volume) 
to 107 cells/ml. Xenografts were generated by injecting 
0.2 ml cell suspension into the area of the mammary fat pad. 
Mice were divided into three groups (control-3, CM-scid, 
rSulf2-scid). A total of 0.1 ml 0.9% saline, CM (50 mM) and 
rSulf2 (50 mM) were separately injected into xenografts every 
day until 6 weeks. Excised xenografts were fixed in formalin 
buffer and embedded in paraffin for advanced testing. All 
experimental protocols followed the instructions of the 
Chinese Council on Animal Care and were approved by the 
Animal Experimental Ethical Inspection of Shanghai Ninth 
People's Hospital affiliated to Shanghai Jiaotong University, 
School of Medicine [permit (no. 20015) 25].
Immunohistochemistry (IHC). Five-micron-thick sections of 
the paraffin-embedded tissues were deparaffinized in xylenes 
and rehydrated through a graded alcohol series. Heat-induced 
epitope retrieval (HIER) was performed by immersion of the 
tissue sections in 8 mM EDTA buffer (pH 8.0) for 20 min 
at 98˚C. IHC staining was performed using a horseradish 
peroxidase-labeled polymer K4001 (Dako, Zagreb, Croatia) 
according to the manufacturer's instructions. Briefly, the 
slides were incubated with 3% hydrogen peroxide and 
1% bovine serum albumin (BSA; Sigma-Aldrich) for 10 min 
each. To visualize lymphatic vessels, the sections were 
exposed to the primary antibody, rabbit anti-mouse LYVE-1 
which was diluted as recommended in 3% BSA, for 1 h at 
room temperature. The slides were then incubated with goat 
anti-rabbit HRP for 30 min followed by incubation with the 
DAB chromogen (Dako) for 5 min. Finally, the slides were 
counterstained with hematoxylin (Thermo Fisher Scientific, 
Waltham, MA, USA), blued in 1% ammonium hydroxide, 
Figure 1. Growth curve of lymphatic endothelial cells (LECs) at different 
time-points. Cell growth curves were drawn based on the absorbance value 
of live cells at different time-points. Compared with the control-1, LECs 
treated with recombinant Sulf2 (rSulf2) or vascular endothelial growth 
factor-D (VEGF-D) showed higher cell proliferation after 48 h, but the dif-
ference was not significant. However, the rSulf2+VEGF-D group showed 
significantly higher cell proliferation than control-1 at 48 and 60 h, *P<0.05.
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dehydrated, and mounted with Acrymount. Consecutive 
sections where the primary antibody was omitted were used 
as negative controls. The washing buffer used was 1X TBS 
with 0.05% Tween-20 (Thermo Fisher Scientific).
Statistical analysis. Data are presented as the mean ± standard 
deviation (SD) of at least three independent experiments with 
three or more replicates. Continuous data were analyzed using 
a two-tailed Student's t-test. P<0.05 was considered to indicate 
a significant difference.
Results
Sulf2 with VEGF-D promotes LEC proliferation. To evaluate 
the role of Sulf2 in LEC proliferation, an MTT assay was used 
to detect the proliferation of LECs at different time-points. 
Cell growth curves were drawn based on the absorbance 
value of live cells at different time-points. Compared with 
the control-1, the rSulf2 and VEGF-D groups showed higher 
cell growth after 36 h, but the difference was not significant. 
However, the group treated with rSulf2+VEGF-D showed 
a significant difference in the absorbance of live cells at 
48 and 60 h (0.36±0.03 vs. 0.24±0.01, 0.41±0.02 vs. 0.25±0.01 
respectively, P<0.05, Fig. 1). The results indicated that Sulf2 
or VEGF-D could enhance LEC proliferation, but their effects 
were not significant. Furthermore, LECs treated with rSulf2 
and VEGF-D showed a significantly higher growth rate than 
the cells treated with control-1. Collectively, these data indi-
cated that Sulf2 could promote breast cancer proliferation 
through the activation of VEGF-D.
Sulf2 inhibits cisplatin-induced LEC apoptosis. To evaluate 
the role of Sulf2 in LEC apoptosis, we measured the 
cisplatin-induced apoptosis and necrosis of LECs by flow 
cytometry. Compared with the control-1, treatment with 
rSulf2 resulted in a significant increase in the percentage of 
Figure 2. The apoptosis of lymphatic endothelial cells (LECs) detected by flow cytometry. (A) Annexin V/propidium iodide-labeled apoptotic LECs were 
detected using flow cytometry. (B) The effects of recombinant Sulf2 (rSulf2), vascular endothelial growth factor-D (VEGF-D) and rSulf2+VEGF-D on LEC 
apoptosis. *P<0.05, **P<0.01.
ZHU et al:  Sulf2 FACILITATES LYMPHANGIOGENESIS IN BREAST CANCER3166
live cells (86.98±3.84 vs. 67.60±2.12, P<0.05) and a significant 
decrease in total apoptosis (9.75±4.03 vs. 17.95±0.78, P<0.05). 
A closer look at the different stages in apoptosis revealed 
that the most significant difference occured in the late stage 
(4.95±2.19 vs. 14.3±1.27, P<0.05) instead of the early stage 
(4.80±1.83 vs. 3.65±2.05, P>0.05). Treatment with VEGF-D 
caused a significant decrease in the percentage of dead cells 
(3.35±1.48 vs. 14.5±1.27, P<0.05), but had no significant effects 
on the percentage of live cells (86.75±4.31 vs. 67.6±2.12, 
P>0.05) and total apoptosis (9.85±5.72 vs. 17.95±0.78, 
P>0.05). Treatment with rSulf2+VEGF-D resulted in 
a significant increase in the percentage of live cells 
(87.11±1.27 vs. 67.60±2.12, P<0.01) and a more significant 
decrease in total apoptosis (10.81±2.40 vs. 17.95±0.78, P<0.05) 
and percentage of dead cells (2.05±0.64 vs. 14.50±1.27, 
P<0.01), especially in the late stage (7.31±1.56 vs. 14.31±1.27, 
P<0.05) (Fig. 2A and B). The results showed that VEGF-D 
had no direct effect on cisplatin-induced LEC apoptosis. 
The rSulf2- and rSulf2+VEGF-D-treated groups showed a 
significant increase in the percentage of live cells, decreased 
cell necrosis and inhibited cisplatin-induced LEC apoptosis, 
particularly in the late stage of apoptosis. However, 
rSulf2+VEGF-D treatment had a greater effect on apoptosis. 
Based on these results, rSulf2 inhibited the apoptosis of LECs 
by activating VEGF-D.
Sulf2 with VEGF-D improves cell cycle distibution of 
cisplatin-pretreated LECs. To ascertain the role of Sulf2 in 
the cell cycle control of LECs, the cell cycle distribution of 
LECs was assessed by flow cytometry. Compared with the 
control-1, rSulf2 treatment caused no difference in the number 
of cells in the G1 phase (78.70±6.40 vs. 81.75±4.55, P>0.05), 
the S phase (6.99±2.42 vs. 6.31±1.08, P>0.05) and the G2/M 
phase (14.45±4.45 vs. 11.99±3.61, P>0.05). Moreover, it had 
no effect on the PI index (21.41±6.76 vs. 18.29±4.65, P>0.05). 
Furthermore, VEGF-D treatment had no significant effect on 
the PI index (24.55±3.23 vs. 18.29±4.65, P>0.05), the number 
of cells in the G1 phase (75.23±5.03 vs. 81.75±4.55, P>0.05), 
the S phase (11.9±1.5 vs. 6.31±1.08, P>0.05) and the G2/M 
phase (12.56±3.26 vs. 11.99±3.61, P>0.05). rSulf2+VEGF-D 
Figure 3. Cell cycle distribution of lymphatic endothelial cells (LECs) as detected by flow cytometry. (A) Cell cycle distribution in the LECs was detected 
using flow cytometry, and the abscissa indicated the amount of DNA. The G1, S and G2/M phases are marked. (B) Effects of recombinant Sulf2 (rSulf2), 
vascular endothelial growth factor-D (VEGF-D) and rSulf2+VEGF-D on the cell cycle of LECs. *P<0.05.
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treatment caused a significant decrease in the number of 
cells in the G1 phase (74.3±5.10 vs. 81.75±4.55, P<0.05), the 
S phase (8.32±1.02 vs. 6.31±1.08, P<0.05) and the G2/M 
phase (16.95±3.55 vs. 11.99±3.61, P<0.05) as well as a 
significantly higher PI index (25.37±2.50 vs. 18.29±4.65, 
P<0.05). We concluded that Sulf2 together with VEGF-D 
significantly promoted cell cycle progression from the G1 
phase to the G2/M phase and increased the PI index in the 
LECs (Fig. 3A and B), while Sulf2 or VEGF-D alone had no 
significant effect on the cell cycle of the LECs.
Sulf2 promotes breast cancer migration. Compared with 
the control-1, the rSulf2- or VEGF-D-treated LECs showed 
higher migration through the membrane of the Boyden 
Figure 4. Lymphatic endothelial cell (LEC) mobility assay using a Transwell chamber. (A) LECs migrated to the lower side of the chamber membranes after 
being incubated for 48 h. (B) The number of LECs that migrated though the chamber membranes. *P<0.05.
Figure 5. The effect of recombinant Sulf2 (rSulf2) in an in vitro lymphatic 
tube formation assay. Compared with control-1, treatment with rSulf2, vas-
cular endothelial growth factor-D (VEGF-D) and rSulf2+VEGF-D resulted 
in a significant increase in the number of new lymphatic tubes formed, espe-
cially in the rSulf2+VEGF-D group.
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chamber (163.33±20.98, 155.67±10.96 vs. 90.0±12.52, 
P<0.05). Moreover, the rSulf2+VEGF-D treated cells showed 
the highest migration rate (247.33±23.07 vs. 90.0±12.52, 
P<0.05) (Fig. 4A and B). These observations clearly suggested 
that rSulf2 or VEGF-D enhanced LEC migration, but rSulf2 
with VEGF-D might work synergistically.
Sulf2 promotes lymphatic tube-like structure formation 
in vitro. To examine the effect of Sulf2 on lymphatic tube-like 
structure formation of LECs in vitro, LECs were seeded 
on Matrigel substrate. Compared with the control-1, more 
lymphatic tube-like structures were formed by LECs treated 
with rSulf2, VEGF-D, and rSulf2+VEGF-D, after 24 h (Fig. 5). 
The results showed that rSulf2 or VEGF-D increased lymphatic 
tube-like structure formation of the LECs, however, the effect 
of Sulf2 with VEGF-D was more significant, suggesting that 
Sulf2 could promote lymphangiogenesis in vitro through the 
activation of VEGF-D.
Sulf2 improves lymphangiogenesis in nude mouse ears. The 
nude mouse ears were examined by pathological sections. 
The lymphatic vessels were detected using IHC. Compared 
with the control-2, the CM-nu and rSulf2-nu groups showed 
significantly more lymphatic vessels (6.8±1.48 vs. 1.6±0.89, 
P<0.01, 10±1.00 vs. 1.6±0.89, P<0.05). Furthermore, rSulf2-nu 
also showed more lymphatic vessels compared with the 
CM-nu group (10±1.00 vs. 6.8±1.48, P<0.05). The results 
demonstrated that both exogenous and endogenous Sulf2 from 
breast cancer xenografts promoted lymphangiogenesis in nude 
mouse ears. Moreover, the effects of purified exogenous Sulf2 
on lymphangiogenesis were more pronounced than endog-
enous Sulf2 (Fig. 6).
Sulf2 promotes lymphangiogenesis in the breast cancer 
xenografts. To detect the effect of Sulf2 on lymphangiogenesis 
in the breast cancer xenografts, we detected the density of 
lymphatic vessels in MDA-MB-231 breast cancer xenografts, 
which did not express Sulf2. No significant lymphatic vessels 
were detected inside or around the xenografts in control-3. 
More lymphatic vessels around the xenografts were detected 
in the CM-scid and rSulf2-scid groups (Fig. 7). The results 
further certified that Sulf2 increased lymphangiogenesis in 
Figure 6. Lymphatic vessels in nude mouse ears detected by immunohistochemical staining. (A) Immunohistochemical staining showing the number of 
lymphatic vessels in nude mouse ears are indicated by the red arrows. (B) Quantification of the number of lymphatic vessels in the three groups, *P<0.05.
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breast cancer xenografts and that breast cancer cells secreted 
Sulf2 to promote lymphangiogenesis.
Sulf2 regulates signaling pathway molecular interac-
tions in LECs. Messenger RNA levels of a panel of VEGF 
signaling pathway genes were first analyzed by PCR 
microarray, followed by qRT-PCR and WB analysis verifica-
tion. Compared with the control-1, the genes significantly 
upregulated following treatment with rSulf2 were PLA2G1B 
(4.44±0.84 vs. 1.00, P<0.01), PLA2G5 (7.54±1.21 vs. 1.00, 
P<0.01) and AKT1 (3.09±0.62 vs. 1.00, P<0.05). The genes 
significantly upregulated by VEGF-D were PLA2G2D 
Figure 7. Sulfatase 2 (Sulf2) promotes lymphangiogenesis in the breast cancer xenografts. The images show lymphatic vessels in the breast cancer xenografts, 
which are marked by red arrows. No lymphatic vessels were detected inside or around the xenografts in control-3. Conditioned medium (CM)-scid and 
recombinant Sulf2 (rSulf2)-scid groups showed more lymphatic vessels around the xenografts.
Figure 8. Change in gene expression caused by Sulfatase 2 (Sulf2) with/without vascular endothelial growth factor-D (VEGF-D) treatment. (A) Gene expres-
sion change in lymphatic endothelial cells (LECs) verified by qRT-PCR. (B) The AKT1 protein expression and phosphorylation were affected by Sulf2 and 
VEGF-D treatment. *P<0.05, **P<0.01. 
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(2.67±0.14 vs. 1.00, P<0.01), AKT1 (2.85±0.04 vs. 1.00, P<0.01) 
and PI3KR1 (1.76±0.06 vs. 1.00, P<0.05). The genes down-
regulated were PLA2G1B (0.49±0.36 vs. 1.00, P<0.05) and 
PI3KR3 (0.57±0.21 vs. 1.00, P<0.05). The genes significantly 
upregulated in the rSulf2+VEGF-D group were PLA2G5 
(4.84±0.12 vs. 1.00, P<0.01), PLA2G2D (2.91±0.21 vs. 1.00, 
P<0.01), PLA2G6 (2.93±0.04 vs. 1.00, P<0.01), AKT1 
(2.59±0.16 vs. 1.00, P<0.01) and PI3KR1 (2.01±0.1 vs. 1.00, 
P<0.01) (Fig. 8A). Only AKT1 mRNA showed the same signif-
icant trends in the three groups and was chosen for further 
WB analysis verification. Furthermore, we tested the AKT1 
and the phosphorylated AKT1 protein by WB analysis in the 
four groups. Compared with the control-1, the expression and 
phosphorylation of AKT1 in the LECs revealed a significant 
increase in the other groups (Fig. 8B). The results revealed that 
Sulf2 and/or VEGF-D could promote AKT1 expression and 
activation in the LECs.
Discussion
Sulf2 has been reported to modify the activities of 
heparan-binding growth factors (VEGF and FGF-1) and 
influence the signaling pathways of the corresponding 
receptors to facilitate angiogenesis. Uchimura et al (5) 
validated Sulf2 as a new molecule involved in angiogenesis 
through the activation of VEGF and FGF-1. Skobe et al (19) and 
Cherng et al (26) certified that the VEGF family is comprised 
of different monomeric forms including VEGF145, VEGF165 
and VEGF189 and VEGF206. These different monomeric 
forms had similar heparan-binding regions, which could be 
regulated by Sulf2. VEGF-D is one member of the VEGF 
family and also shares similar structures. Harris et al (27) 
reported that VEGF-D is an angiogenic and lymphangiogenic 
glycoprotein. Heparan-binding regions in VEGF-D were found 
within the N- and C-terminal propeptides, which suggested 
that VEGF-D could also bind to heparan. The C-terminal 
propeptide significantly enhanced this interaction through 
the removal of this propeptide from full-length VEGF-D. The 
removal of either the N- or C-terminal propeptide was required 
for VEGF-D binding to VEGFR-2/VEGFR-3 and formation of 
heterodimers, which have recently been shown to positively 
regulate angiogenic and lymphangiogenic sprouting (28,29). In 
contrast, the removal of both propeptides was required for high 
rates of lymph node metastasis. It was also reported that the 
propeptides profoundly influenced the molecular interactions 
of VEGF-D with VEGFR-3, and these propeptide structures 
also promoted the effects of VEGF-D on tumor development.
In our previous study, we demonstrated that Sulf2 was 
upstream of VEGF-D and upregulated VEGF-D expression 
in breast cancer cells (6). In this study, we studied the role of 
Sulf2 in lymphangiogenesis and the mechanism involved in 
its function. MCF-7 breast cancer cells released a high level 
of Sulf2 protein into the culture medium, which was demon-
strated in our previous study (6). In this study, we collected the 
CM from the supernatant of MCF-7 cells to study the effect 
of endogenous Sulf2 on lymphangiogenesis in breast cancer 
cells. We also combined and purified exogenous rSulf2 to 
study the direct function and mechanism of Sulf2 in lymphan-
giogenesis. We found that Sulf2 significantly increased LEC 
mobility and lymphatic tube-like structure formation, inhibited 
cisplatin-induced LEC apoptosis in vitro, but had no direct 
effect on cell proliferation and the cell cycle. Moreover, rSulf2 
together with VEGF-D, further promoted the proliferation, cell 
cycle progression, mobility and tube formation in LECs, while 
at the same time inhibited cisplatin-induced apoptosis, espe-
cially in the late stage. Sulf2 also significantly improved the 
densities of lymphatic vessels in mouse ears and breast cancer 
xenografts in vivo. These results showed that Sulf2 not only 
enhanced VEGF-D expression, but also enhanced the activity 
of VEGF-D. Furthermore, we found that the signaling pathway 
gene AKT1 was upregulated and activated by Sulf2.
In summary, Sulf2 markedly promoted lymphangiogenesis 
in breast cancer, possibly by promoting VEGF-D expression 
and by activating the AKT1-related signaling pathway. This 
finding confirmed the role of Sulf2 as a biomarker of breast 
cancer progression. More importantly, new therapeutic 
approaches targeting Sulf2 could improve the clinical 
outcomes in patients with lymph node-positive breast cancer.
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